Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer - Doki, Y; Ueno, M; Hsu, C H (Cancer Med, 2022)